ESTRO meets Asia 2024 - Abstract Book

S273

Interdisciplinary – Upper GI

ESTRO meets Asia 2024

Neoadjuvant immunotherapy combined with chemoradiation demonstrates favorable short-term efficacy and survival, with acceptable safety profiles in esophageal cancer. However, further validation in larger, randomized trials with longer follow-up is needed to confirm these findings.

Keywords: neoadjuvant, esophageal, meta-analysis

134

Proffered Paper

Multimodal radiomics predicts pathological response of esophageal cancer after neoadjuvant therapy

Yunsong Liu 1 , Yi Wang 2 , Qingsong Pang 3 , Xin Wang 1 , Liyan Xue 4 , Huan Zhang 2 , Xinyang Hu 5 , Zeliang Ma 1 , Heping Deng 6 , Zhaoyang Yang 4 , Yu Men 7 , Feng Ye 8 , Kuo Men 1 , Jianjun Qin 9 , Nan Bi 1 , Jing Zhang 10 , Qifeng Wang 2 , Zhouguang Hui 7 1 Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. 2 Department of Radiation Oncology, Radiation Oncology Key Laboratory of Sichuan Province, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China. 3 Department of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China. 4 Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. 5 Department of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China. 6 Department of Diagnostic Radiology, Radiation Oncology Key Laboratory of Sichuan Province, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China. 7 Department of VIP Medical Services, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. 8 Department of Diagnostic Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. 9 Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. 10 Laboratory for Biomechanics and Mechanobiology of Ministry of Education, Beijing Advanced Innovation Center for Biomedical Engineering, School of Engineering Medicine, School of Biological Science and Medical Engineering, Beihang University, Beijing, China

Purpose/Objective:

This study aimed to develop and validate a novel deep learning radiomics model using CT, T2 and DWI images for predicting pathological complete response (pCR) in patients with esophageal squamous cell carcinoma (ESCC) undergoing neoadjuvant chemoradiotherapy (nCRT).

Material/Methods: